Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

you are here: Home News

Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct
Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher
Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher
Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher
Ipca Laboratories Q2 PAT seen up 7.3% YoY to Rs 292.6 cr: Prabhudas Lilladher
Ipca Lab Q1 PAT may dip 53.5% YoY to Rs 207.6 cr: ICICI Direct
IPCA Q4 PAT seen up 126.5% YoY to Rs. 194.8 cr: Sharekhan
IPCA Labs: API capacity constraint almost out of the way
Ipca Labs Q3 PAT seen up 4.9% YoY to Rs. 207.2 cr: Yash Securities
Ipca Labs Q2 PAT seen up 34% YoY to Rs. 160.2 cr: Emkay
IPCA Laboratories Q1 PAT seen up 34.1% YoY to Rs. 87.9 cr: Prabhudas Lilladher
IPCA Laboratories Q4 PAT seen up 106.1% YoY to Rs. 105.8 cr: Prabhudas Lilladher
IPCA Labs Q3 PAT seen up 1.5% YoY to Rs. 107.2 cr: ICICI Direct
IPCA Labs Q2 PAT may dip 7.3% YoY to Rs. 89.4 cr: ICICI Direct
IPCA Laboratories Q4 PAT seen up 209.3% YoY to Rs. 83.8 cr: Edelweiss
IPCA Q1 PAT seen up 153% to Rs 95.4 cr: Edelweiss
Buy IPCA; it is well valued for long-term investors: Angel
Pharma companies revenues to rise 12% in Q3: Anand Rathi
See India biz grow 15%, exports to rise 25% in H2: Ipca
May revise guidance upwards post Q2: Ipca Labs
Pharma cos likely to post 21% EBITDA growth in Q4: MOST
Improvement in gross margins likely to continue: Ipca Labs
Good performance likely from pharma in Q3: Nirmal Bang
See pharma sector's Q3 topline to grow 22%: Motilal Oswal
See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct

Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher

Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher

Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher

Ipca Laboratories Q2 PAT seen up 7.3% YoY to Rs 292.6 cr: Prabhudas Lilladher

Ipca Lab Q1 PAT may dip 53.5% YoY to Rs 207.6 cr: ICICI Direct

IPCA Q4 PAT seen up 126.5% YoY to Rs. 194.8 cr: Sharekhan

IPCA Labs: API capacity constraint almost out of the way

Ipca Labs Q3 PAT seen up 4.9% YoY to Rs. 207.2 cr: Yash Securities

Ipca Labs Q2 PAT seen up 34% YoY to Rs. 160.2 cr: Emkay

IPCA Laboratories Q1 PAT seen up 34.1% YoY to Rs. 87.9 cr: Prabhudas Lilladher

IPCA Laboratories Q4 PAT seen up 106.1% YoY to Rs. 105.8 cr: Prabhudas Lilladher

IPCA Labs Q3 PAT seen up 1.5% YoY to Rs. 107.2 cr: ICICI Direct

IPCA Labs Q2 PAT may dip 7.3% YoY to Rs. 89.4 cr: ICICI Direct

IPCA Laboratories Q4 PAT seen up 209.3% YoY to Rs. 83.8 cr: Edelweiss

IPCA Q1 PAT seen up 153% to Rs 95.4 cr: Edelweiss

Buy IPCA; it is well valued for long-term investors: Angel

Pharma companies revenues to rise 12% in Q3: Anand Rathi

See India biz grow 15%, exports to rise 25% in H2: Ipca

May revise guidance upwards post Q2: Ipca Labs

Pharma cos likely to post 21% EBITDA growth in Q4: MOST

Improvement in gross margins likely to continue: Ipca Labs

Good performance likely from pharma in Q3: Nirmal Bang

See pharma sector's Q3 topline to grow 22%: Motilal Oswal

See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher